Aquinox Pharmaceuticals Announces Year End 2014 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St set to snap three-day streak of losses despite Middle East clashes
- Oil rises, as US-Iran strikes risk limiting already impaired supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Google escapes ad tech breakup in third Big Tech antitrust loss for US
Aquinox Pharmaceutical (AQXP) PT Lifted to $17 at Canaccord Genuity
March 17, 2015 8:46 AM EDTCanaccord Genuity analyst Corey Davis reiterated a Buy rating and lifted his price target on Aquinox Pharmaceutical (NASDAQ: AQXP) to $17.00 (from $12.00) following Q4 results.
Davis commented, "Auinox reported Q4 tonight, and for 2014 logged an adjusted net loss of $22.0M versus our projected $21.4M. While numbers matter little for a R&D-driven story, the... More
